Royalty Pharma PLC
NASDAQ:RPRX

  • LAST PRICE
    26.2100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    26.0100/ 4
  • Ask / Lots
    27.2500/ 1
  • Open / Previous Close
    --- / 26.2100
  • Day Range
    ---
  • 52 Week Range
    25.2000
    31.6550
  • Volume
    31

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

  • Nov 6, 2024

      Show headlines and story abstract

    • 8:08AM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: RPRX
      08:08 AM EST, 11/06/2024 (MT Newswires) -- Royalty Pharma (RPRX) reported Q3 net income Wednesday of $544 million, up from $72 million a year earlier. Comparable analysts' estimates were not available. Total income and other revenue for the quarter ...

    • 7:18AM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: RPRX
      07:18 AM EST, 11/06/2024 (MT Newswires) -- ...

    • 7:15AM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: RPRX

      Amounts may not add due to rounding.
      Royalty Pharma plc Description of Approved Indications for Select Portfolio Therapies Table 5 Cystic fibrosis franchise Cystic fibrosis ------------------------- --------------------------------------------------- Trelegy Chronic obstructive pulmonary disease and asthma ------------------------- --------------------------------------------------- Tysabri Relapsing forms of multiple sclerosis ------------------------- --------------------------------------------------- Evrysdi Spinal muscular atrophy ------------------------- --------------------------------------------------- Imbruvica Hematological malignancies and chronic graft versus host disease ------------------------- --------------------------------------------------- Xtandi Prostate cancer ------------------------- --------------------------------------------------- Promacta Chronic immune thrombocytopenia purpura and aplastic anemia ------------------------- --------------------------------------------------- Tremfya Plaque psoriasis and active psoriatic arthritis ------------------------- --------------------------------------------------- Cabometyx/Cometriq Kidney, liver and thyroid cancer ------------------------- --------------------------------------------------- Spinraza Spinal muscular atrophy ------------------------- --------------------------------------------------- Trodelvy Breast and bladder cancer ------------------------- --------------------------------------------------- Orladeyo Hereditary angioedema ------------------------- --------------------------------------------------- Erleada Prostate cancer ------------------------- --------------------------------------------------- Nurtec ODT/Zavzpret Acute and preventative treatment of migraine ------------------------- ---------------------------------------------------

Peers Headlines